Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

The Original Article was published on 27 September 2017

Correction to: Nature https://doi.org/10.1038/nature24028, published online 27 September 2017.

In the originally published version of this Letter, the authors Arthur F. Kluge, Michael A. Patane and Ce Wang were inadvertently omitted from the author list. Their affiliations are: I-to-D, Inc., PO Box 6177, Lincoln, Massachusetts 01773, USA (A.F.K.); Mitobridge, Inc. 1030 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA (M.A.P.); and China Novartis Institutes for BioMedical Research, No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai 201203, China (C.W.). These authors contributed to the interpretation of results and design of compounds. In addition, author ‘Edward A. Kesicki’ was misspelled as ‘Ed Kesicki’. These errors have been corrected online.

In Fig. 1a (structure 4) of this Letter, the A-485 structure incorrectly included a sulfur atom (S) instead of a carbon (C) at the spiro centre. Figure 1 has been corrected online (see Supplementary Information to this Amendment for the original Fig. 1a, structure 4). In Fig. 4d of this Letter, the units for enzalutamide (Enz) and A-485 were incorrectly listed as millimolar (mM) instead of micromolar (µM). Figure 4 has been corrected online. In Extended Data Fig. 7e of this Letter, the headings ‘−DHT’ and ‘ + DHT’ were missing from the top of the western blots; this figure has been corrected online.

The third sentence of the main text should have read: “This led to two confirmed hits, a hydantoin (Fig. 1a, 1) and a conjugated thiazolidinedione (Fig. 1a, 2), which were similar to the previously described hit that inhibited Rtt1098 and the hit C3756, respectively”, rather than “This led to two confirmed hits, a hydantoin (Fig. 1a, 1) and a conjugated thiazolidinedione (Fig. 1a, 2), which were similar to the previously described hits that inhibited Rtt1098 and C3756, respectively. This has been corrected online.

Finally, the following sentence has been added to the ‘Competing interests’ statement: A.F.K. and M.A.P were consultants to Acylin at the time of the study. C.W. was an employee of BioDuro, which was contracted by Acylin at the time of the study.

Supplementary Information is available in the online version of this Amendment.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kenneth D. Bromberg.

Additional information

These authors contributed equally: Loren M. Lasko, Clarissa G. Jakob.

The original article can be found online at https://doi.org/10.1038/nature24028

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lasko, L.M., Jakob, C.G., Edalji, R.P. et al. Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 558, E1 (2018). https://doi.org/10.1038/s41586-018-0111-5

Download citation

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing